Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600
Debt
Debt-to-Equity RatioN/A
Current Ratio2.69
Quick Ratio2.64
Price-To-Earnings
Trailing P/E Ratio-18.55
Forward P/E Ratio-13.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$154.94 million
Price / Sales7.34
Cash FlowN/A
Price / CashN/A
Book Value$7.46 per share
Price / Book3.73
Profitability
EPS (Most Recent Fiscal Year)($1.50)
Net Income$-59,730,000.00
Net Margins-46.90%
Return on Equity-23.47%
Return on Assets-13.68%
Miscellaneous
Employees173
Outstanding Shares40,860,000
Market Cap$1.14 billion
Retrophin (NASDAQ:RTRX) Frequently Asked Questions
What is Retrophin's stock symbol?
Retrophin trades on the NASDAQ under the ticker symbol "RTRX."
How were Retrophin's earnings last quarter?
Retrophin Inc (NASDAQ:RTRX) released its quarterly earnings data on Thursday, July, 26th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.21. The biopharmaceutical company earned $41.33 million during the quarter, compared to analysts' expectations of $43.22 million. Retrophin had a negative return on equity of 23.47% and a negative net margin of 46.90%. The business's revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 earnings per share. View Retrophin's Earnings History.
When is Retrophin's next earnings date?
What price target have analysts set for RTRX?
2 equities research analysts have issued 12-month target prices for Retrophin's stock. Their predictions range from $43.00 to $43.00. On average, they expect Retrophin's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price. View Analyst Price Targets for Retrophin.
What is the consensus analysts' recommendation for Retrophin?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.
Who are some of Retrophin's key competitors?
Some companies that are related to Retrophin include Agios Pharmaceuticals (AGIO), Ultragenyx Pharmaceutical (RARE), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Emergent Biosolutions (EBS), Array Biopharma (ARRY), Madrigal Pharmaceuticals (MDGL), Horizon Pharma (HZNP), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ironwood Pharmaceuticals (IRWD) and Reata Pharmaceuticals (RETA).
Who are Retrophin's key executives?
Retrophin's management team includes the folowing people:
- Mr. Stephen J. Aselage, CEO, Pres & Director (Age 67)
- Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 59)
- Mr. Neil F. McFarlane, Chief Operating Officer (Age 45)
- Ms. Elizabeth E. Reed, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
- Dr. William E. Rote, Sr. VP of R&D (Age 55)
Who are Retrophin's major shareholders?
Retrophin's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Scopia Capital Management LP (16.13%), BlackRock Inc. (8.69%), Macquarie Group Ltd. (4.00%), Jennison Associates LLC (2.68%), Dimensional Fund Advisors LP (2.28%) and Northern Trust Corp (1.86%). Company insiders that own Retrophin stock include Elizabeth E Reed, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.
Which major investors are selling Retrophin stock?
RTRX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, American Century Companies Inc., Scopia Capital Management LP, Virginia Retirement Systems ET AL, Oak Ridge Investments LLC, Bank of New York Mellon Corp and Bank of New York Mellon Corp. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.
Which major investors are buying Retrophin stock?
RTRX stock was purchased by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., BlackRock Inc., Russell Investments Group Ltd., Macquarie Group Ltd., Handelsbanken Fonder AB, Federated Investors Inc. PA, First Trust Advisors LP and Boston Advisors LLC. View Insider Buying and Selling for Retrophin.
How do I buy shares of Retrophin?
Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Retrophin's stock price today?
One share of RTRX stock can currently be purchased for approximately $27.82.
How big of a company is Retrophin?
Retrophin has a market capitalization of $1.14 billion and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe.
What is Retrophin's official website?
How can I contact Retrophin?
Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]
MarketBeat Community Rating for Retrophin (NASDAQ RTRX)
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
